Inhaled Levosimendan versus Intravenous Levosimendan in Patients with Pulmonary Hypertension Undergoing Mitral Valve Replacement

摘要

Context:Inhaled levosimendan may act as selective pulmonary vasodilator and avoid systemic side effects of intravenous levosimendan, which include decrease in systemic vascular resistance (SVR) and systemic hypotension, but with same beneficial effect on pulmonary artery pressure (PAP) and right ventricular (RV) function.